---
aliases: [REGN]
---
#actor #biotech #antibodies #usa #public

**Regeneron** — Antibody pioneer. Dupixent with [[Sanofi]] ($4.9B/quarter). EYLEA HD transition. VelociSuite platform.

---

## Why Regeneron matters

| Metric | Value |
|--------|-------|
| Ticker | REGN ([[Nasdaq]]) |
| Q3 2025 revenue | $3.75B |
| Dupixent ([[Sanofi]]) | **$4.86B** Q3 (+27% YoY) |
| EYLEA HD | $431M Q3 (+10% YoY) |

---

## Key products

### Dupixent (with [[Sanofi]])

| Metric | Q3 2025 |
|--------|---------|
| Global sales | $4.86B (+27% YoY) |
| Regeneron share | ~$1.6B profit share |
| Indications | Asthma, atopic dermatitis, COPD |

**Primary growth driver** for Regeneron.

### EYLEA franchise

| Product | Q3 2025 | Trend |
|---------|---------|-------|
| EYLEA HD | $431M | +10% YoY |
| EYLEA (original) | Declining | Biosimilar/competition |

**Transition:** Moving patients from EYLEA to EYLEA HD.

**Pressure:** Compounded bevacizumab, biosimilars.

---

## Technology platform

**VelociSuite:** Proprietary antibody discovery platform.
- VelocImmune (humanized mice)
- VelociGene (gene targeting)
- Rapid antibody generation

---

## Pipeline

| Asset | Indication | Status |
|-------|------------|--------|
| Dupixent | New indications | Expanding |
| Libtayo | Oncology | Growing |
| Pozelimab | Rare disease | Approved |

---

## [[Sanofi]] partnership

| Structure | Detail |
|-----------|--------|
| Revenue | [[Sanofi]] records sales |
| Profit share | Regeneron gets ~50% |
| Products | Dupixent, Kevzara, Libtayo |

---

## Investment case

**Bull:**
- Dupixent growth runway (+27%)
- EYLEA HD transition
- VelociSuite platform value
- Pipeline optionality

**Bear:**
- EYLEA erosion from biosimilars
- [[Sanofi]] dependency
- Compounded drug competition
- Valuation premium

---


![[regn-employees-chart.png]]
*Headcount: 15,410 (2025) — up 2.0% YoY*

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | REGN |
| Exchange | [[Nasdaq]] |
| Revenue | ~$15B |
| Focus | Antibodies, ophthalmology |

---

## Related

- [[Biopharma]] — sector

---

## Sources

- [Regeneron Q3 2025 results](https://regeneronpharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/regeneron-reports-third-quarter-2025-financial-and-operating)

*Created 2026-01-09*
